Pelthos Therapeutics Inc.

PTHS | AMEX

Price Alert Chart Builder DCF Calculator

$23.15

+$0.50 (+2.21%)

At close: Sep 21, 2026, 4:00 PM ET

$23.15

$0 (0.00%)

After-hours: Sep 21, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Key Executives

Name	Position
Scott Plesha	Chief Executive Officer, President & Director
John Gay	CFO, Secretary & Treasurer
Sai Rangarao	Chief Commercial Officer

Latest SEC Filings

Date	Type	Title
May 28, 2026	8-K	Current Report
May 26, 2026	4	Filing
May 22, 2026	144	Filing
May 21, 2026	8-K	Current Report
May 18, 2026	4	Filing
May 15, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
May 14, 2026	8-K	Current Report
May 14, 2026	10-Q	Quarterly Report
May 07, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Apr 20, 2026	3	Filing

View All SEC Filings ➞

Pelthos Therapeutics Inc.

Country	United States
IPO Date	Feb 15, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	92
CEO	Scott Plesha

Contact Details

4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 Durham, North Carolina 27703 United States

https://pelthos.com

877 265 8266

Stock Details

Ticker Symbol	PTHS
Exchange	AMEX
Fiscal Year	n/a
Reporting Currency	USD
CIK Code	0001919246
CUSIP Number	171126204
ISIN Number	US1711262048
SIC Code	n/a